Poster
T-DXd
AACR 2025 | April 25-29, 2025
Colorectal Cancer
Exploratory biomarker analysis of trastuzumab deruxtecan (T-DXd) treatment for HER2-positive (HER2+) metastatic colorectal cancer (mCRC) in DESTINY-CRC02 (DC-02)
Salvatore Siena